Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis
Imtiaz A. Samjoo, Luisa Klotz, Gavin Giovannoni, Christopher Drudge, Anja Haltner, Evelyn Worthington, Melody Zhao, Róisín Brennan, Dieter A. Häring, Chris Cameron, Nicholas Adlard
Topics & Concepts
OcrelizumabMedicineRelapsing remittingOfatumumabMultiple sclerosisInternal medicineFilgrastimOncologyPhysical therapyDermatologyRituximabImmunologyGranulocyte colony-stimulating factorChemotherapyLymphomaMultiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersRheumatoid Arthritis Research and Therapies